Myeloma Canada has a wealth of resources, as well as Myeloma UK [and] Myeloma Europe. And so, I will just look at the geography of where that patient is located for specific resources and try to link them into support groups as well. Faith E. Davies, MD: Excellent. Katie, anything ...
Grade 3/4 infections occurred in 39% of the DRd arm and 26% of the Rd group. “These updated findings continue to support the use of DRd in patients with relapsed and refractory multiple myeloma,” Dimopoulos concluded. Dimopoulos MA, White DJ, Benboubker L, et al. Daratumumab, lenalidom...
There were similar rates of CRS, neurotoxicity, and grade 3 or higher infections in the non-frail and frail groups, respectively. The impact of frailty on outcomes with T-cell engagers in the real-world is unknown; however, one analysis noted inferior overall response rates and PFS on ...
Abnormal tumor microenvironment and immune escape in multiple myeloma (MM) are associated with regulatory T cells (Tregs), which play an important role in maintaining self-tolerance and regulating the overall immune response to infection or tumor cells.
the efficacy results, including a median duration of response of 17 months, are promising. The findings support the hypothesis that the memory-like T cell phenotype associated with bb21217 leads to prolonged response durations, and highlight the encouraging therapeutic potential of bb21217 in treati...
10. Kaiser MF, Hall A, Walker K, et al: Depth of response and minimal residual disease status in ultra high-risk multiple myeloma and plasma cell leukemia treated with daratumumab, bortezomib, lenalidomide, cyclophosphamide and dexamethasone: Results of the UK OPTIMUM/MUKnine trial.2021 ASCO Annu...
We also showed that the expression of lncRNAs, together with clinical and genetic risk alterations, stratified MM patients into several progression-free survival and overall survival groups. In summary, our global analysis of the lncRNAs transcriptome reveals the presence of specific lncRNAs associated ...
(ISS). Staging system for myeloma based on the plasma level of β2-microglobulin and albumin, yielding three groups associated with survival outcomes. Interphase fluorescence in situ hybridization (iFISH). A cytogenetic test that maps fluorescent probes to specific parts of the chromosome with the ...
C Kaplan–Meier survival analysis of the control and UroA-treated groups. **P ≤ 0.01 Full size image The combination of UroA and bortezomib has a synergistic effect against MM cells and modulates cancer-related pathways Given the efficacy of UroA treatment on MM cell lines, we assessed ...
Health- related quality of life in multiple myeloma patients receiving high-dose chemotherapy with autologous blood stem-cell support. Med Oncol 2001;18:65-77. 26. Uyl-de Groot CA, Buijt I, Gloudemans IJ, Ossenkoppele GJ, Berg HP, Huijgens PC. Health related quality of life in patients...